CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Orphazyme A/S is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Orphazyme A/S
Ole Maaloees Vej 3, Copenhagen N
KOEBENHAVN, 2200  Denmark Ticker: ORPHAORPHA

This company ceased filing statements with the SEC on 3/31/2022.
On 3/10/2022, Orphazyme A/S closed its commercial operations in Germany, the United Kingdom, and the United States.
On 5/30/2022, the restructuring proposal for Orphazyme A/S was approved and adopted by its creditors and the Danish Maritime and Commercial High Court. The Restructuring Proceedings were discontinued with Immediate effect.
On 5/31/2022, substantially all of the assets of Orphazyme A/S were transferred to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm Inc., pursuant to a sales agreement between the companies. Orphazyme will no longer have any material ongoing operational business activities and KemPharm will retain all of Orphazyme’s remaining Danish employees.

Business Summary
Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board GeorgesGemayel
Chief Executive Officer, Director JakobBendtsen 10/1/2023 10/1/2023
Independent Deputy Chairman of the Board Bo J.Hansen 65
Independent Director AndrewMercieca 53 1/1/2022 1/1/2022

Subsidiaries
Business Name Address City State/Province Country
Orphazyme U.S., Inc. 180 North Street Chicago IL United States

Business Names
Business Name
0CUM
ORPH
ORPHA
ORPHA TEMP
ORPHY

General Information
Number of Employees: 1 (As of 12/31/2022)
Outstanding Shares: 35,312 (As of 12/6/2023)
Stock Exchange: CPH


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, March 18, 2024